Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,867 across all filing types
Latest filing 2015-08-06 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Galapagos NV, with the SEC. It includes exhibits such as press releases and a half-year report for 2015. The document itself is a regulatory filing to report these materials and does not contain the full half-year report or detailed financial statements within the text. The length is only 1343 characters, indicating it is a brief filing rather than a full report. According to the rules, such filings that announce or attach reports but do not contain the full report content should be classified as Regulatory Filings (RNS).
2015-08-06 English
Galapagos rondt werving van patiënten af in FITZROY Fase 2 studie met filgotinib in de ziekte van Crohn
Regulatory Filings Classification · 95% confidence The document is a press release dated August 6, 2015, announcing the completion of patient recruitment for the FITZROY Phase 2 study of filgotinib in Crohn's disease. It details clinical trial progress, expected results timelines (December 2015, Q1 2016), partnership milestones with AbbVie, and provides background information on Crohn's disease and Galapagos NV. This type of announcement, focusing on operational updates, clinical trial milestones, and partnership developments, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a specific operational update rather than a general regulatory filing (RNS), the best fit among the provided options for a company providing key operational and clinical progress updates, often released around earnings periods, is the Earnings Release (ER). It contains key highlights about the business status, even if it's not the formal quarterly results document itself. Given the context of a biotech company reporting clinical progress, ER is the most appropriate classification for this type of material update.
2015-08-06 Dutch
Galapagos op koers om resultaten voor pijplijn te leveren in tweede halfjaar 2015
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive financial report for the first half of 2015, containing detailed financial statements (balance sheet, income statement, cash flow data), management commentary, and operational updates. Although it mentions the availability of a full 'Halfjaarverslag' (Half-year report) at the end, the document itself provides the substantive financial data and analysis required for an Interim/Quarterly Report. It is not merely an announcement or a certification, as it contains detailed tables and financial performance metrics. H1 2015
2015-08-05 Dutch
Half-year report 2015.pdf
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Half-year Report 2015' for Galapagos NV. It contains comprehensive financial statements (consolidated income, financial position, cash flow, and changes in equity), notes to the financial statements, a letter from management, and an auditor's report. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2015
2015-08-05 English
Halfjaarverslag 2015.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halfjaarverslag 2015' (Half-Year Report 2015) for Galapagos NV. It contains comprehensive financial statements (consolidated income statement, balance sheet, cash flow, and equity changes), management discussion and analysis (Brief van het management), and notes to the financial statements. It covers a period shorter than a full fiscal year (H1 2015). It is not an announcement of a report, but the report itself, containing substantive financial data. H1 2015
2015-08-05 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of July 2015. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive reports. The length is short (1249 characters), and it primarily serves as a regulatory filing to disclose information to the SEC and investors. Therefore, it fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not constitute a full annual report, interim report, or other specific report types.
2015-07-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.